Liquid biopsy is a non-invasive method, which can improve EML4-ALK translocation and ALK-TKIs resistance mechanisms detection, which will significantly improve ALK+ NCSCL diagnosis and patients management, leading to a better prognosis and quality of life of ALK+ NSCLC patients. The gene discussed is EML4; the disease is non-small cell lung carcinoma.